Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Michael Soldan has been named CEO of AB2Bio, joining the biotech after serving as CEO of global biosimilars at Fresenius Kabi.
Lisa Johnson-Pratt has been named senior vice president of new product strategy at Akcea Therapeutics. Prior to this appointment, Johnson-Pratt was vice president of global franchise operations at GlaxoSmithKline. In addition, Akcea has announced the promotion of Joshua Patterson to the role of general counsel. Patterson most recently served as vice president of legal and corporate secretary at Akcea.
AliveCor has announced the appointment of Siva Somayajula to the role of chief technology officer. Somayajula was the former director of product software and services for Amazon Consumer Electronics.
Axsome Therapeutics has named Mark Jacobson the company’s new chief operating officer, a promotion from Jacobson’s previous head of operations position at Axsome.
May Orfali has been appointed to the role of consultant chief medical officer. Prior to this appointment, Orfali was the chief medical officer at CANbridge Life Sciences.
Cerecor has found its new chief development officer in H. Jeffery Wilkins, who most recently served as chief medical officer of Zyla Life Sciences.
George Lasezkay has been appointed to the role of president and CEO of Clearside Biomedical. Most recently, Lasezkay was a director at TheraVida.
CureVac founder Ingmar Hoerr will be replacing Daniel Menichella as the company’s CEO.
Francine Behar-Cohen has been appointed to the newly created role of chief innovation officer at Eyevensys, after previously serving as the company’s chief scientific officer. Thierry Bordet, preclinical director at Eyevensys, will assume the role of chief scientific officer.
FUJIFILM Diosynth Biotechnologies
Martin Meeson will succeed newly retired Steve Bagshawas CEO of FUJIFILM Diosynth Biotechnologies. Meeson will continue to serve as president and chief operating officer of FUJIFILM Diosynth Biotechnologies until the transition is finalized.
Anthony Mancinihas been named executive vice president and chief operating officer at Genmab, joining the company from Bristol-Myers Squibb, where he served as senior vice president and head of the U.S. Innovative Medicines Unit.
Ophthalmology gene therapy company HORAMA has announced the appointment of Rodolphe Clerval to the role of chief business officer. Clerval is co-founder and was most recently chief business officer of Enterome.
Lonza Group has appointed Caroline Barth to the role of chief human resources officer. Barth was previously the global HR head of pharma at Novartis in Switzerland.
Marcia de Souza Lima has been named chief medical officer of biopharmaceutical company Oculis. Prior to joining Oculis, de Souza Lima was vice president and head of global medical affairs at Shire.
Rafael Pharmaceuticals has appointed Sanjay Sehgal to the newly created role of chief of regulatory affairs and quality assurance officer. Sehgal previously served as senior vice president of regulatory affairs and conformance at Celularity.
Thomas Wessel has been appointed to the role of executive vice president and head of R&D of Relmada Therapeutics. Prior, Wessel was chief medical officer at Asceneuron.
Senti Biosciences has appointed Jose Iglesias to the role of chief medical officer. Most recently, Iglesias was a director at Apex Oncology Consulting.
Robert McKague has been hired to the role of executive vice president, general counsel and chief compliance officer of Tricida. Most recently, McKague served as senior vice president and associate general counsel at Jazz Pharmaceuticals.
Mark Ellerhas been named senior vice president of R&D at twoXAR Pharmaceuticals. Previously, Eller was senior vice president of research and clinical development at Jazz Pharmaceuticals. Additionally, twoXAR Pharmaceuticals has named Anjali Pandey the company’s new senior vice president of nonclinical R&D and chemistry. Most recently, Pandey was the chief scientific officer at TheRas and Ferro Therapeutics.
Unity Biotechnology has named Anirvan Ghosh as the company’s new CEO. Ghosh was most recently senior vice president and head of early R&D at Biogen.